Ivosidenib Approved as First-Line Treatment for AML with IDH1 Mutation

May 02

2019

The Food and Drug Administration approved ivosidenib (TIBSOVO, Agios Pharmaceuticals, Inc.) for newly-diagnosed acute myeloid leukemia (AML) with a susceptible IDH1 mutation, as detected by an FDA-approved test, in patients who are at least 75 years old or who have comorbidities that preclude the use of intensive induction chemotherapy.

Citations

APA

American Society of Hematology. (2019).
Ivosidenib Approved as First-Line Treatment for AML with IDH1 Mutation.
Retrieved from https://www.hematology.org/education/clinicians/drug-resources/fda-alerts/2019/ivosidenib-approved-first-line-treatment-aml-idh1-mutation.

Chicago

American Society of Hematology.
"Ivosidenib Approved as First-Line Treatment for AML with IDH1 Mutation." Hematology.org.
https://www.hematology.org/education/clinicians/drug-resources/fda-alerts/2019/ivosidenib-approved-first-line-treatment-aml-idh1-mutation
(label-accessed December 14, 2024).

MLA

"American Society of Hematology."
Ivosidenib Approved as First-Line Treatment for AML with IDH1 Mutation, 14 Dec. 2024 ,
https://www.hematology.org/education/clinicians/drug-resources/fda-alerts/2019/ivosidenib-approved-first-line-treatment-aml-idh1-mutation.

Citation Manager Formats

BibLaTeX
Bookends
EasyBib
EndNote
Mendeley
Papers
RIS
Ref Manager
RefWorks
Zotero

Help ASH Build an Inclusive Hematology Community!

ASH is committed to building and nurturing a global hematology community and workforce inclusive of diverse perspectives, talents, and experiences as it works toward one collective goal: helping hematologists conquer blood diseases worldwide.

How Can You Help?

Visit your My Account page, make needed updates to your demographic details, and select your preferred level of ASH access to your information; aggregated or individually identifiable, or choose not to provide or share your information. By sharing information about who you are, you will help ASH have a better appreciation of the diverse needs and talents present in the field, and help to build a more inclusive, collaborative hematology community. It will take only a few moments to complete!

Update Access to Demographic Information Learn About Our Mission